Webinars, Pharmaceutical

Nasal Drug Delivery: Beyond Hayfever

Although nasal drug delivery has historically been used almost exclusively for the delivery of topically acting therapeutics for chronic conditions such as hay fever this situation is changing quite rapidly.

This webinar considers the use of nasal drug delivery for systemically acting, emergency rescue medications, for nose-to-brain drug delivery, for prophylactics and for vaccines for respiratory infections. In each case the unique advantages of nasal drug delivery are discussed with reference to the specific application. Aptar Pharma’s device platforms for nasal drug delivery are introduced and their features related to current market requirements. The challenge of formulation development for nasal drug delivery is also addressed. Aptar Pharma’s expertise in formulation and the company’s track record of success with respect to commercialized nasal drug products is highlighted.

Watch the webinar on Nasal Drug Delivery: Beyond Hayfever
Speaker(s): Gemma Budd
12 Jul 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

12 Jul 2022

Nasal Drug Delivery: Beyond Hayfever

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
21 Jun 2022

Nasal Drug Delivery Challenges and Trends Ahead

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 15

Request Access

Close

Requesting access to Nasal Drug Delivery: Beyond Hayfever.

  • This field is for validation purposes and should be left unchanged.
Back To Top